Benitec Biopharma Inc. (BNTC): EBITDA
-$51.13M
Year ended 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$51.13M | n/m | 2026-09-14, From 2025-07-01 |
| 2025-06-30 | -$41.70M | n/m | 2026-09-14, From 2024-07-01 |
| 2024-06-30 | -$22.40M | n/m | 2026-03-20, From 2023-07-01 |
| 2023-06-30 | -$18.95M | n/m | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | -$17.69M | n/m | 2023-09-21, From 2021-07-01 |
| 2021-06-30 | -$13.37M | n/m | 2022-09-02, From 2020-07-01 |
| 2020-06-30 | -$8.09M | n/m | 2021-09-20, From 2019-07-01 |
| 2019-06-30 | $2.74M | n/a | 2020-09-23, From 2018-07-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | -$51.13M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.29M | n/m |
| PepGen Inc. (PEPG) | 2025-12-31 | -$92.21M | n/m |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | -$115.73M | n/m |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | -$49.18M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$83.06M | n/m |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | -$85.08M | n/m |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | -$67.79M | n/m |
Compare BNTC, LXRX, PEPG, ACET side by side · Screen every company in Pharmaceutical Preparations ↗